Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1332MR)

This product GTTS-WQ1332MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1332MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ14911MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ12188MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ14359MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ11781MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ6826MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ3225MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ5418MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW